{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-066791","form_type":"8-K/A","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.397363+00:00","generated_at":"2026-06-18T05:57:38.894945+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Prime Medicine reports Q4 net loss $39.3M, FY2022 net loss $121.8M; nominates PM359 for CGD","bullets":["Q4 2022 net loss $39.3M improved from $62.9M in Q4 2021; FY2022 net loss $121.8M vs $165.4M prior year.","R&D expenses $29.1M in Q4 and $86.7M for FY2022; G&A $9.6M and $29.8M, respectively.","Cash, short-term investments $293.9M as of Dec 31, 2022, up from $269.6M year-end 2021, boosted by $180.2M IPO net proceeds.","Nominated PM359 as first development candidate for chronic granulomatous disease (CGD); IND-enabling studies planned for 2023.","Preclinical proof-of-concept data for FRDA, CF, and Wilson's disease; first IND filing expected as early as 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-066791","json":"https://secwatch.observer/filing/0001193125-23-066791.json","markdown":"https://secwatch.observer/filing/0001193125-23-066791.md","text":"https://secwatch.observer/filing/0001193125-23-066791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/0001193125-23-066791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/d342589d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:57:38.894945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"752f4b795f2eafca8643df98618b37ec597dcd6c","claim":"Prime Medicine, Inc. reported the year ended December 31, 2022 results: net income Net loss was $121.8 million for the year ended December 31, 2022.","evidence_excerpt":"Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/0001193125-23-066791-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $121.8 million for the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d74022b8b1c3c963a3b52656bdf1a22b9d431a06","claim":"Prime Medicine, Inc. reported the fourth quarter of 2022 results: net income Net loss was $39.3 million for the fourth quarter of 2022.","evidence_excerpt":"Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/0001193125-23-066791-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Net income","value":"Net loss was $39.3 million for the fourth quarter of 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}